Michael Y. Choi

4.8k total citations
114 papers, 2.9k citations indexed

About

Michael Y. Choi is a scholar working on Genetics, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Michael Y. Choi has authored 114 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Genetics, 39 papers in Pathology and Forensic Medicine and 34 papers in Molecular Biology. Recurrent topics in Michael Y. Choi's work include Chronic Lymphocytic Leukemia Research (80 papers), Lymphoma Diagnosis and Treatment (38 papers) and Immunodeficiency and Autoimmune Disorders (16 papers). Michael Y. Choi is often cited by papers focused on Chronic Lymphocytic Leukemia Research (80 papers), Lymphoma Diagnosis and Treatment (38 papers) and Immunodeficiency and Autoimmune Disorders (16 papers). Michael Y. Choi collaborates with scholars based in United States, Australia and Canada. Michael Y. Choi's co-authors include Thomas J. Kipps, Januario E. Castro, Jian Yu, Dennis A. Carson, Desheng Lu, Ahmed Abdelfattah, Chanhyun Park, Matthew S. Davids, George F. Widhopf and Byeong–Moo Kim and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Michael Y. Choi

108 papers receiving 2.9k citations

Peers

Michael Y. Choi
Wayne Pearce United Kingdom
Johan Lennartsson Sweden
Stefan Hart Singapore
N. Shaun B. Thomas United Kingdom
Meike Vogler Germany
Pedro J. Real Spain
Christos K. Kontos Greece
Nanda R. Rodrigues United Kingdom
Manfred Jücker Germany
Wayne Pearce United Kingdom
Michael Y. Choi
Citations per year, relative to Michael Y. Choi Michael Y. Choi (= 1×) peers Wayne Pearce

Countries citing papers authored by Michael Y. Choi

Since Specialization
Citations

This map shows the geographic impact of Michael Y. Choi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Y. Choi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Y. Choi more than expected).

Fields of papers citing papers by Michael Y. Choi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Y. Choi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Y. Choi. The network helps show where Michael Y. Choi may publish in the future.

Co-authorship network of co-authors of Michael Y. Choi

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Y. Choi. A scholar is included among the top collaborators of Michael Y. Choi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Y. Choi. Michael Y. Choi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heyman, Benjamin, Michael Y. Choi, & Thomas J. Kipps. (2024). A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter’s Transformation. SHILAP Revista de lepidopterología. 2024. 1–8.
2.
Botta, Gregory P., Joseph Chao, H. Ma, et al.. (2024). Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells. Journal for ImmunoTherapy of Cancer. 12(2). e007927–e007927. 15 indexed citations
3.
Choi, Michael Y., et al.. (2023). Targeted Therapy in Follicular Lymphoma: Towards a Chemotherapy-Free Approach. Cancers. 15(18). 4483–4483. 3 indexed citations
4.
Heyman, Benjamin, Michael Y. Choi, & Thomas J. Kipps. (2023). Comparison of Venetoclax Based Treatments for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood. 142(Supplement 1). 1907–1907.
5.
Moreno, Carol, Constantine S. Tam, Andrew Grigg, et al.. (2023). Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study. Blood Advances. 7(18). 5294–5303. 10 indexed citations
6.
Narezkina, Anna, Nausheen Akhter, Xiaoxiao Lu, et al.. (2022). Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke. Clinical Lymphoma Myeloma & Leukemia. 22(11). e959–e971. 10 indexed citations
7.
8.
Chen, Yun, Liguang Chen, Jian Yu, et al.. (2019). Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia. Blood. 134(13). 1084–1094. 52 indexed citations
9.
Choi, Michael Y., Huan‐You Wang, & Thomas J. Kipps. (2019). SOHO State of the Art Updates and Next Questions: The Conundrum in Assessing the Therapy Response of Patients With Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 19(6). 321–325. 1 indexed citations
10.
Kim, Byeong–Moo, et al.. (2018). Hepatic stellate cells secrete Ccl5 to induce hepatocyte steatosis. Scientific Reports. 8(1). 7499–7499. 40 indexed citations
11.
Choi, Michael Y., George F. Widhopf, Emanuela M. Ghia, et al.. (2018). Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell stem cell. 22(6). 951–959.e3. 144 indexed citations
12.
13.
Wierda, William G., Matthew S. Davids, Richard R. Furman, et al.. (2017). Venetoclax (VEN) Is Active in Chronic Lymphocytic Leukemia (CLL) Relapsed or Refractory to More Than One B-Cell Receptor Pathway Inhibitor (BCRi). Blood. 130. 3025–3025. 3 indexed citations
14.
Wu, Christina, Ekaterina V. Vinogradova, Fitzgerald S. Lao, et al.. (2017). Proteomic Analysis Reveals IRAK4 As a Therapeutic Target in Chronic Lymphocytic Leukemia. Blood. 130. 3838–3838. 1 indexed citations
15.
Kashyap, Manoj Kumar, Deepak Kumar, Brett H. Simmons, et al.. (2017). Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. Journal of Hematology & Oncology. 10(1). 112–112. 49 indexed citations
16.
Mato, Anthony R., William G. Wierda, Matthew S. Davids, et al.. (2017). Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy. Blood. 130(Suppl_1). 834–834. 12 indexed citations
17.
Daneshvar, K., Joshua V. Pondick, Byeong–Moo Kim, et al.. (2016). DIGIT Is a Conserved Long Noncoding RNA that Regulates GSC Expression to Control Definitive Endoderm Differentiation of Embryonic Stem Cells. Cell Reports. 17(2). 353–365. 54 indexed citations
18.
Tam, Betty Y., Cheryl Black, Deping Wang, et al.. (2012). Synthesis, SAR and biological evaluation of 1,6-disubstituted-1H-pyrazolo[3,4-d]pyrimidines as dual inhibitors of Aurora kinases and CDK1. Bioorganic & Medicinal Chemistry Letters. 22(5). 2070–2074. 35 indexed citations
19.
Kim, Byeong–Moo, Marc Thier, Sangnam Oh, et al.. (2012). MicroRNAs Are Indispensable for Reprogramming Mouse Embryonic Fibroblasts into Induced Stem Cell-Like Cells. PLoS ONE. 7(6). e39239–e39239. 27 indexed citations
20.
Lu, Desheng, Michael Y. Choi, Jian Yu, et al.. (2011). Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proceedings of the National Academy of Sciences. 108(32). 13253–13257. 330 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wayne Pearce Breakdown of academic impact, for papers by Johan Lennartsson Breakdown of academic impact, for papers by Stefan Hart Breakdown of academic impact, for papers by N. Shaun B. Thomas Breakdown of academic impact, for papers by Meike Vogler Breakdown of academic impact, for papers by Pedro J. Real Breakdown of academic impact, for papers by Christos K. Kontos Breakdown of academic impact, for papers by Nanda R. Rodrigues Breakdown of academic impact, for papers by Manfred Jücker
Rankless by CCL
2026